A lot of insider buying in Dendreon lately, Directors, Officers, CEO, Cheif Scientific Officer among others. I bought some this morning at $5.70. DNDN has $3.21 cash per share, virtually no debt and a lot of good science to go along with substantial insider buying at these levels.
Dendreon Corporation is a biotechnology company focused on the discovery, development and commercialization of targeted therapies for cancer. The Company's portfolio includes product candidates to treat a range of cancers using therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. Its most advanced product candidate is Provenge, a therapeutic vaccine for the treatment of prostate cancer. Provenge is being evaluated under a pivotal, randomized, double blind, placebo-controlled Phase III clinical trial in men with androgen independent prostate cancer whose cancer has a Gleason score of seven and less. Dendreon's preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease and pro-drug product candidates for the treatment of cancer. In July 2003, Dendreon completed its acquisition of Corvas International, Inc.